


“ **HOW DO I KNOW IF  
LEMTRADA IS THE RIGHT  
TREATMENT OPTION?** ”

  
**LEMTRADA**<sup>®</sup>  
alemtuzumab<sup>12mg</sup><sub>iv</sub>

Please see Important Safety Information on pages [18-21](#) and click for full [Prescribing Information/Medication Guide](#), including serious side effects.





## What is LEMTRADA?

LEMTRADA is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Since treatment with LEMTRADA can increase your risk of getting certain conditions and diseases, LEMTRADA is generally prescribed for people who have tried 2 or more MS medicines that have not worked well enough. LEMTRADA is not recommended for use in patients with clinically isolated syndrome (CIS). It is not known if LEMTRADA is safe and effective for use in children under 17 years of age.

## SELECTED IMPORTANT SAFETY INFORMATION

LEMTRADA can cause serious side effects including autoimmune problems, infusion reactions, stroke, tears in your arteries that supply blood to your brain (carotid and vertebral arteries), some kinds of cancers, thyroid problems, low blood counts (cytopenias), inflammation of the liver, hemophagocytic lymphohistiocytosis, Adult Onset Still's Disease, thrombotic thrombocytopenic purpura, autoimmune encephalitis, bleeding disorder (acquired hemophilia A), inflammation of the colon (colitis), serious infections, progressive multifocal leukoencephalopathy (PML), inflammation of the gallbladder without gallstones (acalculous cholecystitis), and swelling of lung tissue (pneumonitis).

Because of the risks of autoimmune problems, infusion reactions and some kinds of cancers, LEMTRADA is only available through a restricted program called the Risk Evaluation and Mitigation Strategy (REMS) Program.

Individual results may vary. Please consult your physician to see if LEMTRADA is right for you.

Please see Important Safety Information on pages [18-21](#) and click for full [Prescribing Information/Medication Guide](#), including serious side effects.

**LEMTRADA**<sup>®</sup>  
alemtuzumab<sup>12mg</sup>  
iv



## IDENTIFY RELAPSING MULTIPLE SCLEROSIS RISK FACTORS THAT COULD CONTRIBUTE TO MORE AGGRESSIVE DISEASE.

It's important to have conversations about these risks, which include gender and ethnicity, as well as more clinically based factors, such as multiple relapses in a year or incomplete recovery from relapse

- Male
- Incomplete recovery from relapses
- Worsening disability progression
- African American
- Frequent relapses
- High level of MRI lesion activity



## EVALUATE TREATMENT HISTORY

- Age at diagnosis
- Progressing disease despite treatment
- Number of prior treatments



## DETERMINE WHAT MATTERS IN THE TREATMENT JOURNEY

- Level of commitment
- Dosing
- Treatment effectiveness
- HCP partnership
- Monitoring
- Potential side effects



## SELECTED IMPORTANT SAFETY INFORMATION


LEMTRADA can cause serious side effects including autoimmune problems, infusion reactions, stroke, tears in your arteries that supply blood to your brain (carotid and vertebral arteries), some kinds of cancers, thyroid problems, low blood counts (cytopenias), inflammation of the liver, hemophagocytic lymphohistiocytosis, Adult Onset Still's Disease, thrombotic thrombocytopenic purpura, autoimmune encephalitis, bleeding disorder (acquired hemophilia A), inflammation of the colon (colitis), serious infections, progressive multifocal leukoencephalopathy (PML), inflammation of the gallbladder without gallstones (acalculous cholecystitis), and swelling of lung tissue (pneumonitis).

Because of the risks of autoimmune problems, infusion reactions and some kinds of cancers, LEMTRADA is only available through a restricted program called the Risk Evaluation and Mitigation Strategy (REMS) Program.

Individual results may vary. Please consult your physician to see if LEMTRADA is right for you.

Please see Important Safety Information on pages [18-21](#) and click for full [Prescribing Information/Medication Guide](#), including serious side effects.

**LEMTRADA**<sup>®</sup>  
alemtuzumab<sup>12mg</sup><sub>iv</sub>







**KIM** | 44  
MAGNOLIA, TX  
married, mother of 3,  
pre-school teacher

## DISEASE HISTORY

 **20 YEARS**  
since RMS diagnosis





## PATIENT BACKGROUND

 **RMS RISK FACTORS**  
African American, incomplete  
recovery from relapses

## RMS TREATMENT HISTORY

 2 prior DMTs:  
1 injectable and  
1 oral therapy

**HEAR FROM KIM >**



## SELECTED IMPORTANT SAFETY INFORMATION

LEMTRADA can cause serious side effects including autoimmune problems, infusion reactions, stroke, tears in your arteries that supply blood to your brain (carotid and vertebral arteries), some kinds of cancers, thyroid problems, low blood counts (cytopenias), inflammation of the liver, hemophagocytic lymphohistiocytosis, Adult Onset Still's Disease, thrombotic thrombocytopenic purpura, autoimmune encephalitis, bleeding disorder (acquired hemophilia A), inflammation of the colon (colitis), serious infections, progressive multifocal leukoencephalopathy (PML), inflammation of the gallbladder without gallstones (acalculous cholecystitis), and swelling of lung tissue (pneumonitis).

Because of the risks of autoimmune problems, infusion reactions and some kinds of cancers, LEMTRADA is only available through a restricted program called the Risk Evaluation and Mitigation Strategy (REMS) Program.

Individual results may vary. Please consult your physician to see if LEMTRADA is right for you.

Please see Important Safety Information on pages [18-21](#) and click for full [Prescribing Information/Medication Guide](#), including serious side effects.

  
alem<sup>12mg</sup>tuzumab<sup>iv</sup>

“ I LIVE AN ACTIVE LIFE AND MY DISEASE PROGRESSION  
MADE CARING FOR MY 3 CHILDREN INCREASINGLY DIFFICULT. ”



### WHAT MOTIVATED YOU TO EXPLORE OTHER TREATMENT OPTIONS?

I was having multiple relapses and I was determined to find another treatment option. My HCP team agreed to discuss options and see what to do next.



### WHY LEMTRADA?

After reviewing both the safety and efficacy data with my doctor, my family and I felt the potential benefits outweighed the risks for me. The required monthly monitoring and self-checks would allow me and my HCP to keep an eye on my health. And if getting to my HCP or lab was too difficult, I knew that I could have a visiting lab technician come to my home.



### DID YOU HAVE ANY CONCERNS ABOUT STARTING LEMTRADA?

Potential autoimmune side effects were my greatest concern. As a result of one of my regular self-checks, I discovered a blister in my mouth and I contacted my doctor immediately. He told me it was ITP, or immune thrombocytopenic purpura, which meant that I had low blood platelet levels.



### WHAT WOULD YOU TELL SOMEONE ABOUT YOUR EXPERIENCE?

I'm at the end of my scheduled monitoring since taking LEMTRADA 5 years ago. The ITP was treated, I've had no relapses, and my doctor hasn't seen any signs of disability progression. I'm glad I learned more about LEMTRADA and was able to make an informed decision. In the future, if my doctor thinks I need an additional course of treatment and monitoring, I will do it again.

### SELECTED IMPORTANT SAFETY INFORMATION





LEMTRADA can cause serious side effects including autoimmune problems, infusion reactions, stroke, tears in your arteries that supply blood to your brain (carotid and vertebral arteries), some kinds of cancers, thyroid problems, low blood counts (cytopenias), inflammation of the liver, hemophagocytic lymphohistiocytosis, Adult Onset Still's Disease, thrombotic thrombocytopenic purpura, autoimmune encephalitis, bleeding disorder (acquired hemophilia A), inflammation of the colon (colitis), serious infections, progressive multifocal leukoencephalopathy (PML), inflammation of the gallbladder without gallstones (acalculous cholecystitis), and swelling of lung tissue (pneumonitis).

Because of the risks of autoimmune problems, infusion reactions and some kinds of cancers, LEMTRADA is only available through a restricted program called the Risk Evaluation and Mitigation Strategy (REMS) Program.

Individual results may vary. Please consult your physician to see if LEMTRADA is right for you.

Please see Important Safety Information on pages [18-21](#) and click for full [Prescribing Information/Medication Guide](#), including serious side effects.

**LEMTRADA**<sup>®</sup>  
alemtuzumab<sup>12mg</sup><sub>iv</sub>







**LUIS** | 38  
EL PASO, TX  
married, father of 3,  
volunteer volleyball coach

## DISEASE HISTORY

 **7 YEARS**  
since RMS diagnosis

## PATIENT BACKGROUND

 **RMS RISK FACTORS**  
male, worsening disability progression

## RMS TREATMENT HISTORY

 2 prior DMTs:  
2 injectables

**HEAR FROM LUIS >**

## SELECTED IMPORTANT SAFETY INFORMATION




LEMTRADA can cause serious side effects including autoimmune problems, infusion reactions, stroke, tears in your arteries that supply blood to your brain (carotid and vertebral arteries), some kinds of cancers, thyroid problems, low blood counts (cytopenias), inflammation of the liver, hemophagocytic lymphohistiocytosis, Adult Onset Still's Disease, thrombotic thrombocytopenic purpura, autoimmune encephalitis, bleeding disorder (acquired hemophilia A), inflammation of the colon (colitis), serious infections, progressive multifocal leukoencephalopathy (PML), inflammation of the gallbladder without gallstones (acalculous cholecystitis), and swelling of lung tissue (pneumonitis).

Because of the risks of autoimmune problems, infusion reactions and some kinds of cancers, LEMTRADA is only available through a restricted program called the Risk Evaluation and Mitigation Strategy (REMS) Program.

Individual results may vary. Please consult your physician to see if LEMTRADA is right for you.

Please see Important Safety Information on pages **18-21** and click for full [Prescribing Information/Medication Guide](#), including serious side effects.

  
alem<sup>12mg</sup>tuzumab<sup>iv</sup>



“RELAPSING MS HAS MADE IT DIFFICULT FOR ME  
TO BE AS INVOLVED IN MY DAUGHTERS’ LIVES AS I WANT TO BE.”



### WHAT MOTIVATED YOU TO EXPLORE OTHER TREATMENT OPTIONS?

As a man, I know I am at risk for a worsening form of relapsing MS. Despite being on other treatments, I was experiencing multiple relapses that resulted in disability progression.



### WHY CONSIDER LEMTRADA?

Things were getting worse for me and it was important that I explored other therapy options that could possibly address my RMS. My doctor and I spent a lot of time discussing LEMTRADA pros and cons, and ultimately I felt that it was the right therapy for me given my active disease.



### WHO PLAYED A ROLE IN YOUR DECISION?

My wife and I discussed with my neurologist potential side effects to look out for, such as certain types of cancers and infusion reactions. We talked about the monthly monitoring, too. My doctor is someone I can talk honestly to, and she helped me to prepare for treatment, so my overall experience was what I expected.



### WHAT WOULD YOU SAY TO SOMEONE CONSIDERING SWITCHING?

Was I nervous? Was my family nervous? Of course. It's normal to be nervous. Make sure you have open and honest conversations with your healthcare team and your family. Ask all your questions, even the ones you think are minor.

## SELECTED IMPORTANT SAFETY INFORMATION



LEMTRADA can cause serious side effects including autoimmune problems, infusion reactions, stroke, tears in your arteries that supply blood to your brain (carotid and vertebral arteries), some kinds of cancers, thyroid problems, low blood counts (cytopenias), inflammation of the liver, hemophagocytic lymphohistiocytosis, Adult Onset Still's Disease, thrombotic thrombocytopenic purpura, autoimmune encephalitis, bleeding disorder (acquired hemophilia A), inflammation of the colon (colitis), serious infections, progressive multifocal leukoencephalopathy (PML), inflammation of the gallbladder without gallstones (acalculous cholecystitis), and swelling of lung tissue (pneumonitis).

Because of the risks of autoimmune problems, infusion reactions and some kinds of cancers, LEMTRADA is only available through a restricted program called the Risk Evaluation and Mitigation Strategy (REMS) Program.

Individual results may vary. Please consult your physician to see if LEMTRADA is right for you.

Please see Important Safety Information on pages [18-21](#) and click for full [Prescribing Information/Medication Guide](#), including serious side effects.

**LEMTRADA**<sup>®</sup>  
alemtuzumab<sup>12mg</sup><sub>iv</sub>







**GINNY** | 38  
PHOENIX, AZ  
married, mother of 3,  
teacher, motorcycle  
enthusiast


## DISEASE HISTORY

 **6 YEARS**  
since RMS diagnosis

## PATIENT BACKGROUND

 **RMS  
RISK FACTORS**  
incomplete recovery from  
relapses

## RMS TREATMENT HISTORY

 5 prior DMTs:  
2 oral treatments,  
2 injectables, and  
1 infusion therapy

**HEAR FROM GINNY >**

## SELECTED IMPORTANT SAFETY INFORMATION





LEMTRADA can cause serious side effects including autoimmune problems, infusion reactions, stroke, tears in your arteries that supply blood to your brain (carotid and vertebral arteries), some kinds of cancers, thyroid problems, low blood counts (cytopenias), inflammation of the liver, hemophagocytic lymphohistiocytosis, Adult Onset Still's Disease, thrombotic thrombocytopenic purpura, autoimmune encephalitis, bleeding disorder (acquired hemophilia A), inflammation of the colon (colitis), serious infections, progressive multifocal leukoencephalopathy (PML), inflammation of the gallbladder without gallstones (acalculous cholecystitis), and swelling of lung tissue (pneumonitis).

Because of the risks of autoimmune problems, infusion reactions and some kinds of cancers, LEMTRADA is only available through a restricted program called the Risk Evaluation and Mitigation Strategy (REMS) Program.

Individual results may vary. Please consult your physician to see if LEMTRADA is right for you.

Please see Important Safety Information on pages [18-21](#) and click for full [Prescribing Information/Medication Guide](#), including serious side effects.

  
alemtuzumab<sup>12mg</sup><sub>iv</sub>





“ I HAD TRIED MULTIPLE TREATMENTS UNSUCCESSFULLY IN A SHORT PERIOD OF TIME. I FELT LIKE A PAWN IN THE PROCESS. ”



### WHAT MOTIVATED YOU TO EXPLORE OTHER TREATMENT OPTIONS?

Despite taking multiple therapies, I was still experiencing relapses and disability progression. I wanted to find out more about the efficacy and safety of LEMTRADA, and was intrigued by the dosing schedule because it was different from what I was used to.



### HOW DID YOU HANDLE ANY CONCERNS ABOUT SAFETY?

I wasn't sure that I fully understood the full safety profile so I sought the advice of specialists who educated me about things like the potential autoimmune side effects and required monthly monitoring. After learning more, I felt comfortable moving forward with LEMTRADA.



### DID YOU FEEL PREPARED FOR YOUR INFUSIONS?

Before my first course, my doctor explained the infusion process. By the second course of LEMTRADA, I knew to take into account how I would feel when scheduling my infusion days. It took some planning on my part, but by the second infusion I felt well prepared.



### WHAT WOULD YOU TELL SOMEONE CONSIDERING LEMTRADA?

Spend the time you need to get the information you want to help you make the most informed decision. Understand what LEMTRADA entails and make sure you can fully commit to all that is required.

## SELECTED IMPORTANT SAFETY INFORMATION




LEMTRADA can cause serious side effects including autoimmune problems, infusion reactions, stroke, tears in your arteries that supply blood to your brain (carotid and vertebral arteries), some kinds of cancers, thyroid problems, low blood counts (cytopenias), inflammation of the liver, hemophagocytic lymphohistiocytosis, Adult Onset Still's Disease, thrombotic thrombocytopenic purpura, autoimmune encephalitis, bleeding disorder (acquired hemophilia A), inflammation of the colon (colitis), serious infections, progressive multifocal leukoencephalopathy (PML), inflammation of the gallbladder without gallstones (acalculous cholecystitis), and swelling of lung tissue (pneumonitis).

Because of the risks of autoimmune problems, infusion reactions and some kinds of cancers, LEMTRADA is only available through a restricted program called the Risk Evaluation and Mitigation Strategy (REMS) Program.

Individual results may vary. Please consult your physician to see if LEMTRADA is right for you.

Please see Important Safety Information on pages [18-21](#) and click for full [Prescribing Information/Medication Guide](#), including serious side effects.

**LEMTRADA**<sup>®</sup>  
alemtuzumab<sup>12mg</sup><sub>iv</sub>





**CHARLES** | 23  
MARSHALL, MN  
pursuing a bachelor's degree  
in management


## DISEASE HISTORY

 **1 YEAR**  
since RMS diagnosis




## PATIENT BACKGROUND

 **RMS  
RISK FACTORS**  
male, African American, incomplete  
recovery from relapses

## RMS TREATMENT HISTORY

 1 prior DMT:  
1 injectable therapy  
for 1 year

**HEAR FROM CHARLES >**



## SELECTED IMPORTANT SAFETY INFORMATION

LEMTRADA can cause serious side effects including autoimmune problems, infusion reactions, stroke, tears in your arteries that supply blood to your brain (carotid and vertebral arteries), some kinds of cancers, thyroid problems, low blood counts (cytopenias), inflammation of the liver, hemophagocytic lymphohistiocytosis, Adult Onset Still's Disease, thrombotic thrombocytopenic purpura, autoimmune encephalitis, bleeding disorder (acquired hemophilia A), inflammation of the colon (colitis), serious infections, progressive multifocal leukoencephalopathy (PML), inflammation of the gallbladder without gallstones (acalculous cholecystitis), and swelling of lung tissue (pneumonitis).

Because of the risks of autoimmune problems, infusion reactions and some kinds of cancers, LEMTRADA is only available through a restricted program called the Risk Evaluation and Mitigation Strategy (REMS) Program.

Individual results may vary. Please consult your physician to see if LEMTRADA is right for you.

Please see Important Safety Information on pages [18-21](#) and click for full [Prescribing Information/Medication Guide](#), including serious side effects.

  
alemtuzumab<sup>12mg</sup><sub>iv</sub>



“ I WAS YOUNG AND HAD ACTIVE RMS WHEN  
I PARTNERED WITH A DOCTOR WHO UNDERSTOOD THE URGENCY  
FOR ME TO GET ON THE RIGHT TREATMENT FOR ME. ”



### WHAT MOTIVATED YOU TO EXPLORE OTHER TREATMENT OPTIONS?

It seemed RMS was winning the war and I was having frequent relapses and not getting better. I was in college and I wasn't willing to compromise my dreams.



### WHY LEMTRADA?

My doctor suggested LEMTRADA. My mother and I educated ourselves on the trial data, and with the help of my doctor, I felt that I could manage all the requirements.



### HOW DID YOU HANDLE ANY CONCERNS?

LEMTRADA has requirements, like the monthly labs and self-checks, so staying on top of those is critical. I was most worried about how the monitoring would impact my school schedule. After discussing every aspect of treatment with my doctor, I knew what to expect. Knowledge is power!



### WHAT WOULD YOU TELL SOMEONE CONSIDERING LEMTRADA?

Be your own best advocate and never give up the search for a treatment plan that can work for you. Finding a treatment takes time and I am so thankful that I spoke up and found a doctor who was a great partner.

## SELECTED IMPORTANT SAFETY INFORMATION



LEMTRADA can cause serious side effects including autoimmune problems, infusion reactions, stroke, tears in your arteries that supply blood to your brain (carotid and vertebral arteries), some kinds of cancers, thyroid problems, low blood counts (cytopenias), inflammation of the liver, hemophagocytic lymphohistiocytosis, Adult Onset Still's Disease, thrombotic thrombocytopenic purpura, autoimmune encephalitis, bleeding disorder (acquired hemophilia A), inflammation of the colon (colitis), serious infections, progressive multifocal leukoencephalopathy (PML), inflammation of the gallbladder without gallstones (acalculous cholecystitis), and swelling of lung tissue (pneumonitis).

Because of the risks of autoimmune problems, infusion reactions and some kinds of cancers, LEMTRADA is only available through a restricted program called the Risk Evaluation and Mitigation Strategy (REMS) Program.

Individual results may vary. Please consult your physician to see if LEMTRADA is right for you.

Please see Important Safety Information on pages [18-21](#) and click for full [Prescribing Information/Medication Guide](#), including serious side effects.

**LEMTRADA**<sup>®</sup>  
alemtuzumab<sup>12mg</sup><sub>iv</sub>





**ASHLEY** | 38  
RIVER FOREST, IL  
social worker, mother of 2


## DISEASE HISTORY

 **15 YEARS**  
since RMS diagnosis

## PATIENT BACKGROUND

 **RMS RISK FACTORS**  
worsening disability progression,  
incomplete recovery from relapses

## RMS TREATMENT HISTORY

 4 prior DMTs:  
3 injectables and  
1 infusion therapy

**HEAR FROM ASHLEY >**

## SELECTED IMPORTANT SAFETY INFORMATION




LEMTRADA can cause serious side effects including autoimmune problems, infusion reactions, stroke, tears in your arteries that supply blood to your brain (carotid and vertebral arteries), some kinds of cancers, thyroid problems, low blood counts (cytopenias), inflammation of the liver, hemophagocytic lymphohistiocytosis, Adult Onset Still's Disease, thrombotic thrombocytopenic purpura, autoimmune encephalitis, bleeding disorder (acquired hemophilia A), inflammation of the colon (colitis), serious infections, progressive multifocal leukoencephalopathy (PML), inflammation of the gallbladder without gallstones (acalculous cholecystitis), and swelling of lung tissue (pneumonitis).

Because of the risks of autoimmune problems, infusion reactions and some kinds of cancers, LEMTRADA is only available through a restricted program called the Risk Evaluation and Mitigation Strategy (REMS) Program.

Individual results may vary. Please consult your physician to see if LEMTRADA is right for you.

Please see Important Safety Information on pages [18-21](#) and click for full [Prescribing Information/Medication Guide](#), including serious side effects.

**LEMTRADA**<sup>®</sup>  
alemtuzumab<sup>12mg</sup><sub>iv</sub>





“ I WAS A YOUNG MOTHER AND RMS WAS TAKING UP MY TIME. I WISH I HAD EDUCATED MYSELF ABOUT MY TREATMENT OPTIONS SOONER. ”



### WHAT MOTIVATED YOU TO EXPLORE OTHER TREATMENT OPTIONS?

I had a relapse so bad that I couldn't walk across the parking lot. The worsening of my disability progression was beginning to scare me and an incomplete recovery was my motivation to find another therapy.



### WHY LEMTRADA?

Other therapies hadn't worked well enough on my relapses and disability progression and I had a family to consider. After a discussion with my doctor, I was comfortable with LEMTRADA's efficacy and safety, including the monitoring requirements.



### HOW DID YOU HANDLE ANY CONCERNS ABOUT SAFETY?

My doctor and I discussed what to watch for, such as autoimmune problems, stroke, and possible infections. I was committed to the required monthly monitoring as it could help detect possible serious side effects after my last treatment course.



### WHAT WOULD YOU TELL SOMEONE CONSIDERING SWITCHING?

Don't hesitate to find out about LEMTRADA and see if it is right for you. You are your best advocate.

## SELECTED IMPORTANT SAFETY INFORMATION




LEMTRADA can cause serious side effects including autoimmune problems, infusion reactions, stroke, tears in your arteries that supply blood to your brain (carotid and vertebral arteries), some kinds of cancers, thyroid problems, low blood counts (cytopenias), inflammation of the liver, hemophagocytic lymphohistiocytosis, Adult Onset Still's Disease, thrombotic thrombocytopenic purpura, autoimmune encephalitis, bleeding disorder (acquired hemophilia A), inflammation of the colon (colitis), serious infections, progressive multifocal leukoencephalopathy (PML), inflammation of the gallbladder without gallstones (acalculous cholecystitis), and swelling of lung tissue (pneumonitis).

Because of the risks of autoimmune problems, infusion reactions and some kinds of cancers, LEMTRADA is only available through a restricted program called the Risk Evaluation and Mitigation Strategy (REMS) Program.

Individual results may vary. Please consult your physician to see if LEMTRADA is right for you.

Please see Important Safety Information on pages [18-21](#) and click for full [Prescribing Information/Medication Guide](#), including serious side effects.

**LEMTRADA**<sup>®</sup>  
alemtuzumab<sup>12mg</sup><sub>iv</sub>





**DONNIE** | 49

WINCHESTER, KY  
**married, father of 2, former  
high school football player**


## DISEASE HISTORY

 **15 YEARS**  
since RMS diagnosis

## PATIENT BACKGROUND

 **RMS  
RISK FACTORS**  
male, severe disability  
progression

## RMS TREATMENT HISTORY

 4 prior DMTs:  
1 oral therapy,  
2 injectables, and  
1 infusion treatment

**HEAR FROM DONNIE >**

## SELECTED IMPORTANT SAFETY INFORMATION



LEMTRADA can cause serious side effects including autoimmune problems, infusion reactions, stroke, tears in your arteries that supply blood to your brain (carotid and vertebral arteries), some kinds of cancers, thyroid problems, low blood counts (cytopenias), inflammation of the liver, hemophagocytic lymphohistiocytosis, Adult Onset Still's Disease, thrombotic thrombocytopenic purpura, autoimmune encephalitis, bleeding disorder (acquired hemophilia A), inflammation of the colon (colitis), serious infections, progressive multifocal leukoencephalopathy (PML), inflammation of the gallbladder without gallstones (acalculous cholecystitis), and swelling of lung tissue (pneumonitis).

Because of the risks of autoimmune problems, infusion reactions and some kinds of cancers, LEMTRADA is only available through a restricted program called the Risk Evaluation and Mitigation Strategy (REMS) Program.

Individual results may vary. Please consult your physician to see if LEMTRADA is right for you.

Please see Important Safety Information on pages [18-21](#) and click for full [Prescribing Information/Medication Guide](#), including serious side effects.

  
alemtuzumab<sup>12mg</sup><sub>iv</sub>





“ I WAS WORRIED ABOUT DISEASE PROGRESSION AND  
THE POSSIBLE IMPACT THAT COULD HAVE ON MY FAMILY. ”



### WHAT MOTIVATED YOU TO EXPLORE OTHER TREATMENT OPTIONS?

I was experiencing multiple relapses every year and my disability continued to progress. My primary concern was how my family could be affected. It was a turning point.



### WHY LEMTRADA?

First, I liked that it showed an effect on relapse rate and disability progression. Also, that it would be 5 days of infusion the first year and 3 days one year later. And I knew I could adhere to the monitoring requirements.



### HOW DID YOU HANDLE ANY CONCERNS ABOUT SAFETY AND SUPPORT?

The monthly monitoring seemed like a big commitment, but my doctor said it was necessary to help detect serious side effects early. Overall, I felt I would be supported throughout my LEMTRADA treatment by my doctor and my healthcare team. Having a team behind me helped a lot!



### WHAT WOULD YOU TELL SOMEONE CONSIDERING SWITCHING?

I'm glad I made the switch and didn't give up on finding the right treatment for me. Listen to your doctor, and work with them to find a treatment plan that works for *you*.

## SELECTED IMPORTANT SAFETY INFORMATION



LEMTRADA can cause serious side effects including autoimmune problems, infusion reactions, stroke, tears in your arteries that supply blood to your brain (carotid and vertebral arteries), some kinds of cancers, thyroid problems, low blood counts (cytopenias), inflammation of the liver, hemophagocytic lymphohistiocytosis, Adult Onset Still's Disease, thrombotic thrombocytopenic purpura, autoimmune encephalitis, bleeding disorder (acquired hemophilia A), inflammation of the colon (colitis), serious infections, progressive multifocal leukoencephalopathy (PML), inflammation of the gallbladder without gallstones (acalculous cholecystitis), and swelling of lung tissue (pneumonitis).

Because of the risks of autoimmune problems, infusion reactions and some kinds of cancers, LEMTRADA is only available through a restricted program called the Risk Evaluation and Mitigation Strategy (REMS) Program.

Individual results may vary. Please consult your physician to see if LEMTRADA is right for you.

Please see Important Safety Information on pages [18-21](#) and click for full [Prescribing Information/Medication Guide](#), including serious side effects.

**LEMTRADA**<sup>®</sup>  
alemtuzumab<sup>12mg</sup><sub>iv</sub>



LEMTRADA WAS RIGHT **FOR THESE PATIENTS** AND COULD BE  
THE RMS TREATMENT **FOR YOU**



**KIM, 44**

African American  
Incomplete recovery from relapses



**LUIS, 38**

Male  
2 prior treatments



**GINNY, 38**

>3 prior treatments  
Incomplete recovery from relapses



**CHARLES, 23**

Male  
African American



**ASHLEY, 38**

Worsening disability progression  
>3 prior treatments



**DONNIE, 49**

Male  
Worsening disability progression

**SELECTED IMPORTANT SAFETY INFORMATION**

LEMTRADA can cause serious side effects including autoimmune problems, infusion reactions, stroke, tears in your arteries that supply blood to your brain (carotid and vertebral arteries), some kinds of cancers, thyroid problems, low blood counts (cytopenias), inflammation of the liver, hemophagocytic lymphohistiocytosis, Adult Onset Still's Disease, thrombotic thrombocytopenic purpura, autoimmune encephalitis, bleeding disorder (acquired hemophilia A), inflammation of the colon (colitis), serious infections, progressive multifocal leukoencephalopathy (PML), inflammation of the gallbladder without gallstones (acalculous cholecystitis), and swelling of lung tissue (pneumonitis).

Because of the risks of autoimmune problems, infusion reactions and some kinds of cancers, LEMTRADA is only available through a restricted program called the Risk Evaluation and Mitigation Strategy (REMS) Program.

Individual results may vary. Please consult your physician to see if LEMTRADA is right for you.

Please see Important Safety Information on pages **18-21** and click for full [\*\*Prescribing Information/Medication Guide\*\*](#), including serious side effects.

**LEMTRADA**<sup>®</sup>  
alemtuzumab<sup>12mg</sup><sub>iv</sub>



## “ HOW DO I KNOW IF LEMTRADA MAY BE RIGHT FOR ME? ”



### **Put together a list of questions for your doctor**

- Risk factors
- Treatment history
- Considerations



### **Talk to your doctor about LEMTRADA**



### **Visit [LEMTRADA.com](https://www.lemtrada.com) for more information**

## **SELECTED IMPORTANT SAFETY INFORMATION**

LEMTRADA can cause serious side effects including autoimmune problems, infusion reactions, stroke, tears in your arteries that supply blood to your brain (carotid and vertebral arteries), some kinds of cancers, thyroid problems, low blood counts (cytopenias), inflammation of the liver, hemophagocytic lymphohistiocytosis, Adult Onset Still's Disease, thrombotic thrombocytopenic purpura, autoimmune encephalitis, bleeding disorder (acquired hemophilia A), inflammation of the colon (colitis), serious infections, progressive multifocal leukoencephalopathy (PML), inflammation of the gallbladder without gallstones (acalculous cholecystitis), and swelling of lung tissue (pneumonitis).

Because of the risks of autoimmune problems, infusion reactions and some kinds of cancers, LEMTRADA is only available through a restricted program called the Risk Evaluation and Mitigation Strategy (REMS) Program.

Individual results may vary. Please consult your physician to see if LEMTRADA is right for you.

Please see Important Safety Information on pages [18-21](#) and click for full [Prescribing Information/Medication Guide](#), including serious side effects.

**LEMTRADA**<sup>®</sup>  
alemtuzumab<sup>12mg</sup><sub>iv</sub>

# IMPORTANT SAFETY INFORMATION

## LEMTRADA can cause serious side effects including:

**Serious autoimmune problems:** Some people receiving LEMTRADA develop a condition where the immune cells in your body attack other cells or organs in the body (autoimmunity), which can be serious and may cause death. Serious autoimmune problems may include:

- Immune thrombocytopenic purpura (ITP), a condition of reduced platelet counts in your blood that can cause severe bleeding that may cause life-threatening problems. Call your healthcare provider (HCP) right away if you have any of the following symptoms: easy bruising, bleeding from a cut that is hard to stop, coughing up blood, heavier menstrual periods than normal, bleeding from your gums or nose that is new or takes longer than usual to stop, small, scattered spots on your skin that are red, pink, or purple.
- Kidney problems called anti-glomerular basement membrane disease, which, if not treated, can lead to severe kidney damage, kidney failure that needs dialysis, a kidney transplant, or death. Call your HCP right away if you have any of the following symptoms: swelling of your legs or feet, blood in the urine (red or tea-colored urine), decrease in urine, fatigue, coughing up blood.

It is important for you to have blood and urine tests before you receive, while you are receiving and every month for 4 years or longer, after you receive your last LEMTRADA infusion.

**Serious infusion reactions:** LEMTRADA can cause serious infusion reactions that may cause death. Serious infusion reactions may happen while you receive, or up to 24 hours or longer after you receive LEMTRADA.

- You will receive your infusion at a healthcare facility with equipment and staff trained to manage infusion reactions, including serious allergic reactions, and urgent heart or breathing problems. You will be watched while you receive, and for 2 hours or longer after you receive, LEMTRADA. If a serious infusion reaction happens while you are receiving LEMTRADA, your infusion may be stopped.

Tell your HCP right away if you have any of the following symptoms of a serious infusion reaction during the infusion, and after you have left the healthcare facility:

- swelling in your mouth or throat
- trouble breathing
- weakness
- fast, slow, or irregular heartbeat
- chest pain
- rash

To lower your chances of getting a serious infusion reaction, your HCP will give you a medicine called corticosteroids before your first 3 infusions of a treatment course. You may also be given other medicines before or after the infusion to try to reduce your chances of having these reactions or to treat them if they happen.

Individual results may vary. Please consult your physician to see if LEMTRADA is right for you.

Please see Important Safety Information on pages [18-21](#) and click for full [Prescribing Information/Medication Guide](#), including serious side effects.

  
**LEMTRADA**<sup>®</sup>  
alemtuzumab<sup>12mg</sup><sub>iv</sub>



## IMPORTANT SAFETY INFORMATION (CONTINUED)

**Stroke and tears in your arteries that supply blood to your brain (carotid and vertebral arteries):** Some people have had serious and sometimes deadly strokes and tears in their carotid or vertebral arteries within 3 days of receiving LEMTRADA. Get help right away if you have any of the following symptoms that may be signs of a stroke or tears in your carotid or vertebral arteries: drooping of parts of your face, weakness on one side, sudden severe headache, difficulty with speech, neck pain.

**Certain cancers:** Receiving LEMTRADA may increase your chance of getting some kinds of cancers, including thyroid cancer, skin cancer (melanoma), and blood cancers called lymphoproliferative disorders and lymphoma. Call your HCP if you have the following symptoms that may be a sign of thyroid cancer: new lump, swelling in your neck, pain in front of neck, trouble swallowing or breathing, hoarseness or other voice changes that do not go away, cough that is not caused by a cold.

Have your skin checked before you start receiving LEMTRADA and each year while you are receiving treatment to monitor for symptoms of skin cancer.

**Because of risks of autoimmunity, infusion reactions, and some kinds of cancers, LEMTRADA is only available through a restricted program called the LEMTRADA Risk Evaluation and Mitigation Strategy (REMS) Program.**

**Do not receive LEMTRADA if you:**

- are allergic to alemtuzumab or to any of the inactive ingredients in LEMTRADA
- are infected with human immunodeficiency virus (HIV)
- have an active infection

**Thyroid problems:** Some patients taking LEMTRADA may get an overactive thyroid (hyperthyroidism) or an underactive thyroid (hypothyroidism). Call your HCP if you have: excessive sweating, unexplained weight loss, unexplained weight gain, fast heartbeat, eye swelling, nervousness, feeling cold, worsening tiredness, constipation.

**Low blood counts (cytopenias):** LEMTRADA may cause a decrease in some types of blood cells. Some people with these low blood counts have increased infections. Call your doctor right away if you have symptoms of cytopenias such as: weakness, chest pain, yellowing of the skin or whites of the eyes (jaundice), dark urine, fast heartbeat.

**Inflammation of the liver:** Call your HCP right away if you have symptoms such as unexplained nausea, stomach pain, tiredness, loss of appetite, yellowing of skin or whites of eyes, or bleeding or bruising more easily than normal.

**Hemophagocytic lymphohistiocytosis:** LEMTRADA may increase the risk of overactivity of the immune system that can be fatal if not diagnosed and treated early. If you experience symptoms such as fever, swollen glands, or skin rash, contact your HCP right away.

Individual results may vary. Please consult your physician to see if LEMTRADA is right for you.

Please see Important Safety Information on pages [18-21](#) and click for full [Prescribing Information/Medication Guide](#), including serious side effects.



## IMPORTANT SAFETY INFORMATION (CONTINUED)

**Adult Onset Still's Disease (AOSD):** LEMTRADA may cause AOSD, a rare condition that can cause a high fever lasting more than 1 week, pain, stiffness with or without swelling in multiple joints, and/or a skin rash. If you experience a combination of these symptoms, contact your HCP immediately.

**Thrombotic thrombocytopenic purpura (TTP):** LEMTRADA may cause blood clotting problems that can be fatal. Call your HCP right away if you experience symptoms such as: purplish spots on skin or in mouth due to bleeding under skin, yellowing of skin or whites of eyes (jaundice), feel tired or weak, very pale skin, fever, fast heart rate or short of breath, headache, speech changes, confusion, vision changes, seizure, low amount of urine or dark or bloody urine, stomach pain, nausea, vomiting, or diarrhea.

**Autoimmune encephalitis (AIE):** LEMTRADA may cause AIE, a brain disorder which may include symptoms that seem like an MS relapse. Call your HCP right away if you have any of the following symptoms: personality changes, mood changes, seeing things that are not there (hallucinations), agitation, short term memory loss, confusion, movement disorders, or seizures.

**Bleeding disorder (acquired hemophilia A):** LEMTRADA may cause acquired hemophilia A. Call your HCP right away if you have any of the following symptoms: bruising, nose bleeds, bleeding from a cut that may take longer than usual to stop, painful or swollen joints, blood in urine, dark or bloody stools.

**Inflammation of the colon (colitis):** Tell your HCP if you have symptoms of colitis, such as diarrhea (loose stools) or more frequent bowel movements, stools that are black, tarry, sticky or have blood or mucous, or severe stomach-area pain or tenderness.

**Serious infections:** LEMTRADA may cause you to have a serious infection while you receive and after receiving a course of treatment. Serious infections may include:

- **listeria.** People who receive LEMTRADA have an increased chance of getting a bacterial infection called listeria, which can lead to significant complications or death. Avoid foods that may be a source of listeria or make sure foods are heated well.
- **herpes viral infections.** Some people taking LEMTRADA have an increased chance of getting herpes viral infections. Take medicines as prescribed by your HCP to reduce your chances of getting these infections.
- **tuberculosis.** Your HCP should check you for tuberculosis before you receive LEMTRADA.
- **hepatitis.** People who are at high risk of, or are carriers of, hepatitis B (HBV) or hepatitis C (HCV) may be at risk of irreversible liver damage.

These are not all the possible infections that could happen while on LEMTRADA. Call your HCP right away if you have symptoms of a serious infection such as fever or swollen glands. Talk to your HCP before you get vaccinations after receiving LEMTRADA. Certain vaccinations may increase your chances of getting infections.

**Progressive multifocal leukoencephalopathy (PML):** A rare brain infection that usually leads to death or severe disability has been reported with LEMTRADA. Symptoms of PML get worse over days to weeks. It is important that you call your doctor right away if you have any new or worsening medical problems that have lasted several days, including problems with thinking, eyesight, strength, balance, weakness on one side of your body, using your arms or legs.

Individual results may vary. Please consult your physician to see if LEMTRADA is right for you.

Please see Important Safety Information on pages [18-21](#) and click for full [Prescribing Information/Medication Guide](#), including serious side effects.

  
**LEMTRADA**<sup>®</sup>  
alemtuzumab<sup>12mg</sup><sub>iv</sub>



## IMPORTANT SAFETY INFORMATION (CONTINUED)

**Inflammation of the gallbladder without gallstones (acalculous cholecystitis):** LEMTRADA may increase your chance of getting inflammation of the gallbladder without gallstones, a serious medical condition that can be life-threatening. Call your HCP right away if you have stomach pain or discomfort, fever, nausea, or are vomiting.

**Swelling of lung tissue (pneumonitis):** Some people have had swelling of the lung tissue while receiving LEMTRADA. Call your HCP right away if you have shortness of breath, cough, wheezing, chest pain or tightness, or are coughing up blood.

### Before receiving LEMTRADA, tell your HCP if you:

- have bleeding, thyroid, or kidney problems
- have a recent history of infection
- are taking a medicine called Campath® (alemtuzumab)
- have received a live vaccine in the past 6 weeks before receiving LEMTRADA or plan to receive any live vaccines. Ask your HCP if you are not sure if your vaccine is a live vaccine.
- are pregnant or plan to become pregnant. LEMTRADA may harm your unborn baby. You should use birth control while receiving LEMTRADA and for 4 months after your course of treatment.
- are breastfeeding or plan to breastfeed. You and your HCP should decide if you should receive LEMTRADA or breastfeed.

**Tell your HCP about all the medicines you take,** including prescription and over-the-counter medicines, vitamins, and herbal supplements. LEMTRADA and other medicines may affect each other, causing side effects. Especially tell your HCP if you take medicines that increase your chance of getting infections, including medicines used to treat cancer or to control your immune system.

### The most common side effects of LEMTRADA include:

- |                                    |                               |  |
|------------------------------------|-------------------------------|--|
| • rash                             | • upper respiratory infection | • sinus infection                        |
| • headache                         | • herpes viral infection      | • mouth pain or sore throat              |
| • thyroid problems                 | • hives                       | • tingling sensation                     |
| • fever                            | • itching                     | • dizziness                              |
| • swelling of your nose and throat | • fungal infection            | • stomach pain                           |
| • nausea                           | • joint pain                  | • sudden redness in face, neck, or chest |
| • urinary tract infection          | • pain in your arms or legs   | • vomiting                               |
| • feeling tired                    | • back pain                   |  |
| • trouble sleeping                 | • diarrhea                    |  |

Tell your HCP if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of LEMTRADA.

Individual results may vary. Please consult your physician to see if LEMTRADA is right for you.

Please see Important Safety Information on pages **18-21** and click for full **Prescribing Information/Medication Guide**, including serious side effects.



**VISIT LEMTRADA.COM**  
for more information

Please see Important Safety Information on pages **18-21** and click for full **Prescribing Information/Medication Guide**, including serious side effects.

**sanofi**

Trademarks are the property of their respective owners.

© 2024 Sanofi. All rights reserved.

LEMTRADA, CAMPATH, MS One to One and Sanofi are registered trademarks of Sanofi or an affiliate.

MAT-US-2006665-v8.0-09/2024

  
**LEMTRADA<sup>®</sup>**  
alemtuzumab<sup>12mg</sup>  
iv